Search results
Results From The WOW.Com Content Network
Some studies showed a low vaccination rate against some Vaccine-preventable disease among patients taking immunosuppressive drugs, despite a generally positive attitude towards vaccinations. [13] There are also other side-effects, such as hypertension, dyslipidemia, hyperglycemia, peptic ulcers, lipodystrophy, moon face, liver injury and kidney ...
[4] [9] Adverse effects may be class-dependent, and so switching to a biologic of another class may ameliorate those effects. [7] Potential serious adverse effects include allergic reactions, liver damage, cancer, and serious infections including tuberculosis, pneumonia, staph infection, and fungal infection. [4] [9]
Immunosuppression is a reduction of the activation or efficacy of the immune system. Some portions of the immune system itself have immunosuppressive effects on other parts of the immune system, and immunosuppression may occur as an adverse reaction to treatment of other conditions.
CimaVax is an active vaccine with which patients are immunized with epidermal growth factor (EGF), thus raising antibodies targeting EGF itself. The EGF is chemically linked to the Neisseria meningitidis outer protein P64k for immunogenicity; [2] Montanide ISA 51 is used as an adjuvant to potentiate the immune response.
Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, COVID‑19, and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus (RSV). [10] [11] It is a respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor [6] that is designed to bind to the fusion protein on the surface of the RSV virus.
Golimumab, sold under the brand name Simponi, is a human monoclonal antibody which is used as an immunosuppressive medication. [3] [5] Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule [6] and hence is a TNF inhibitor.
Muromonab-CD3 is a murine (mouse) monoclonal IgG2a antibody which was created using hybridoma technology. [9] It binds to the T cell receptor-CD3-complex (specifically the CD3 epsilon chain) on the surface of circulating T cells, initially leading to an activation, [ 7 ] but subsequently inducing the clearance of TCR complex from cell surface ...